Navigation Links
Study Sheds Light on Painkillers' Heart Risk
Date:11/3/2008

Cox-2 drugs, like Celebrex, less safe than Cox-1 drugs, like naproxen, study says

MONDAY, Nov. 3 (HealthDay News) -- The increased risk of heart attack that comes with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to treat arthritis pain is directly related to the specific pain-causing molecule they act against, a new study finds.

"We found a significant correlation between the degree of inhibition in vitro [in the laboratory] of whole blood cox-2, but not whole blood cox-1," said the report by researchers in Spain and Italy.

Cox-1 and cox-2 are different forms of cyclooxygenase, an enzyme whose activity increases inflammation and pain. Older NSAIDs, such as ibuprofen and naproxen, act primarily against cox-1. A newer generation of NSAIDs that act against cox-2 reduce the gastrointestinal bleeding, pain and inflammation that are major side effects of the cox-1 drugs, but they have been found to increase the risk of heart attack and stroke.

Three cox-2 inhibitor NSAIDs have been marketed in the United States. Two of them -- Bextra and Vioxx -- were withdrawn from the market earlier this decade because of their association with an increased risk of heart attack and stroke. A third cox-2, Celebrex, remains available, but with a label warning of cardiovascular risk.

All NSAIDs increase heart risk, according to the new study of 8,852 people who had heart attacks. And the increase was related to both the dosage and the length of time the drugs were taken. But the risk was increased by 18 percent by drugs acting primarily against cox-1, compared to a 60 percent increase for those with the greatest cox-2 activity.

The findings were published in the Nov. 11 issue of the Journal of the American College of Cardiology.

Dr. Michael E. Farkouh, director of clinical trials at the Mount Sinai Cardiovascular Institute in New York City, said the new study "lends support to the theory t
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GSU study first to confirm long-term benefits of morphine treatment in infants
2. Study finds fears of HIV transmission in families with infected parent
3. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
4. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
5. Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults
6. Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival
7. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
8. Patience during stalled labor can avoid many C-sections, UCSF study shows
9. UNC Lineberger launches 44-county study of breast cancer in black women
10. Pioneer(R) Surgical Technologys NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
11. Study Finds Preventative Diabetes Care Reduces Amputation Occurrence

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...swire/--WhenmostpeopleheartheacronymTMJ,theythinko...hehelptheyneed.TMJstandsfortheTemporal-MandibularJ...swithyourskull(temporalbone). ,, Themostcommons...ing,clickingorpoppingofthejaw.Butmanyothersymptoms...atigue,sleepdisturbances,irritability,alossinfocus...
(Date:11/25/2009)...leMedicalInc.,aleadingmanufacturerofbreastMRIcoils...wleadingedgeclinicalapplicationsonitsAegis(TM)medi...SocietyofNorthAmerica(RSNA)annualmeetinginChicago,...leveragetheuniquehighqualityimagesgeneratedbySenti...eimagingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...eBayAreaAirQualityManagementDistrictisissuingthese... forThursday,November26,2009whichbansburningwood...rsandoutdoors. ,, "Cold,stillweatherwillcontrib...t,executiveofficeroftheAirDistrict."We,reaskingBay...fellowcommunitymembersthisThanksgiving,andnottobur...
(Date:11/25/2009)... a collaboration between UCLA engineers and physic... million Americans who suffer from peripheral arte...he arteries, peripheral arterial disease, or PAD, ...arteries reduce blood flow to the limbs. The condi..., heart attack and stroke, and its progression can...
(Date:11/25/2009)...eatment clinics to resume Monday, Nov. 30 , ...2009 -- Centegra Health System is continuing to of...four Centegra Primary Care (CPC) vaccination clini...The clinics are at CPC sites in Huntley, Woodstock...lows: ,   From 4:30 to 7:30 p.m. Tuesd...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...NTO, Calif., Feb. 20 CUREXO Technology Corporatio... image-directed robotic products for orthopaedic a...otic system, announced today that it has submitted... Surgical System for Total Knee Arthroplasty (TKA)...
... Calif., Feb. 25 Already a leader in the High T... Brand Intelligence software, is now offering its ...panies. , , Stu Clifton, New Momentum CEO, repo...twice the pace of legitimate pharmaceuticals -- an...
...ip anchor made from bioabsorbable Hydroxyapatite (...ew,s (NYSE: SNN ; LSE: SN) Endoscopy Division ha...or repair in the hip and shoulder. The device is s...rm an estimated 15,000 labral repair procedures in...
...gests jobs such as baby-sitting, lawn mowing could...lthDay News) -- A new study suggests it,s possible...juvenile delinquent. , Researchers found that fift...gs don,t prove that overwork directly leads to tro...
...turing efforts include the re-alignment of shared ...lishment of Pharmaceutical Governance and Medical ...nd PRINCETON, N.J., Feb. 25 Otsuka America Pharma...he North American pharmaceutical organizations, on...
... Feb. 25 The patent expiry of blockbuster molecul...confronting intense competition from generics. CEO...ative approaches to maintain the growth of their o...ter drugs represents a potential strategy that can...
Other Medicine News:Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2Health News:New Momentum Launches Anti-Counterfeiting Software for Pharmaceutical Companies 2Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 2Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 3Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 4Health News:Work May Not Be Best for Young Kids 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 2Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 4
(Date:11/25/2009)...e/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/...ctiveRandomizedOralTherapyEvaluationinCrohn,sdisea...oderate-to-severeCrohn,sdiseasedemonstratedclinica...e.Thestudydemonstratedevidenceofclinicalefficacyin...ecreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpat...
(Date:11/24/2009)..., WHAT:RomHoubens,aBelgianmanthoughttohavebeeninco...lyconsciousandawakeduringthattimeandwasthesubjecto...turedinthesegmenttoillustratehowpeoplewithLocked-i... ,, WHEN:GoodMorningAmerica-- Tuesday,November2..., WHO:RomHoubenswasanengineeringstudentin1986when...
(Date:11/24/2009)...Call/--QuestDiagnosticsIncorporated(NYSE: DGX ),th...tionandservices,announcedthatitisscheduledtospeaka...wYorkCity.ThepresentationisscheduledforWednesday,D...econference,thecompanywillreaffirmits2009guidancef...ceed18%ofrevenues,anddilutedearningspersharefromco...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 1AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 1US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 3
...orporation (Nasdaq:,DNDN) today will present a sum...uleucel-T), an investigational active cellular imm...um in New York City. The presentation, which,integ...s the safety,profile, immune response and clinical...sitive cancer who have failed standard therapy., ...
...Pharmaceuticals,Inc. (Nasdaq: VIAP ), a biotechno...ds for the treatment of cardiovascular disease, an...and webcast to discuss results of the,VIA-2291 Pha...arterectomy,(CEA) trials presented at the American...on Sunday, November 9. The conference call and web...
Other Medicine Technology:Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 2Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 3Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 4VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA 2
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: